Immix Biopharma Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Immix Biopharma, Inc. (IMMX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-21.61-15.43-8.23-24.38-1.15
Depreciation & Amortization0.120.010.000.000.00
Stock Based Compensation3.022.570.620.220.00
Change in Working Capital3.971.650.20-0.390.17
Change in Accounts Receivable-0.970.000.000.000.00
Change in Accounts Payable4.402.431.13-0.110.00
Change in Other Working Capital0.540.110.10-0.380.11
Other Operating Activities-0.08-0.170.1022.910.58
Net Cash from Operating Activities-14.60-11.37-7.41-1.59-0.40
Investing Activities
Capital Expenditures-1.18-0.050.000.000.00
Net Cash from Investing Activities-1.18-0.050.000.000.00
Financing Activities
Debt Repayment0.000.00-0.050.000.00
Common Stock Issued15.9515.703.3918.650.00
Common Stock Repurchased0.000.00-0.100.000.00
Other Financing Activities0.00-0.23-0.010.000.00
Net Cash from Financing Activities15.9515.463.2318.850.00
Summary
Effect of Forex Changes on Cash0.000.03-0.03-0.010.00
Net Change in Cash0.184.04-4.1817.25-0.34
Cash at Beginning of Period17.5113.4417.640.390.00
Cash at End of Period17.6817.5113.4417.640.00
Free Cash Flow-15.77-11.42-7.41-1.59-0.40
Supplemental Disclosures
Interest Paid0.000.000.010.000.00
Income Taxes Paid0.000.000.000.000.02